Item 7.01 Regulation FD Disclosure.
Axsome Therapeutics, Inc. (the "Company") remains on track and is in the process
of submitting a New Drug Application ("NDA") for AXS-05 in major depressive
disorder, expected imminently. The Company intends to issue a press release
following the U.S. Food and Drug Adminstration's decision regarding its
acceptance of the filing.
The information in this Item 7.01 of this Current Report on Form 8-K shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information contained in this Item 7.01 shall not be incorporated by reference
into any filing with the Securities and Exchange Commission made by the Company,
whether made before or after the date hereof, regardless of any general
incorporation language in such filing.
1
© Edgar Online, source Glimpses